17:36 ETThe Inner Circle acknowledges Shankari Thiagarajan as Pinnacle Professional of The Yearprnewswire·1 day ago, 04:37 PM4503ALPMY-2.24%
SMC recommends VEOZA for moderate to severe menopausal vasomotor symptomsPharmaTimes·Jul 13 at 07:07 AM4503ALPMY-2.24%
FDA approves Pfizer PADCEV-Keytruda combo for perioperative muscle-invasive bladder cancerPUBT·Jul 10 at 10:23 AMPFE-0.48%4503
Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengthsrttnews·Jun 26 at 08:59 AMALPMY-2.24%
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitorbiopharmadive·Jun 24 at 09:32 AMMKKGY+1.59%SNY+9.00%
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circlebenzinga_article·Jun 23 at 12:46 PMSGMO0.00%ALPMY-2.24%
Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to AstellasTradingView·Jun 23 at 07:53 AMSGMO0.00%ALPMY-2.24%
Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bidsPUBT·Jun 23 at 07:05 AMSGMO0.00%LLY-1.05%
Inside Astellas CEO's plan to counter Xtandi’s patent cliffFiercepharma·Jun 11 at 05:02 PM4503ALPMY-2.24%
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial | BAYRY Stock NewsStockTitan·May 30 at 08:25 AMBAYRY-1.91%ALPMY-2.24%
Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology PartnershipSimplywall·May 24 at 07:25 PMVIR-0.74%ALPMY-2.24%
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock NewsStockTitan·May 17 at 11:00 PMALPMY-2.24%4503
